Sialic acid: A novel marker of cardiovascular disease?

Clinical Biochemistry

Volumn 39, Issue 7, 2006, Pages 667-681

  Gopaul, Karina P ^a   Crook, Martin A ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

Author keywords

Cardiovascular disease; Inflammatory markers; Sialic acid

Indexed keywords

BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN; SIALIC ACID;

ANALYTIC METHOD; ATHEROSCLEROSIS; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHROMATOGRAPHY; COLORIMETRY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ENDOTHELIUM; ENZYME ASSAY; EPIDEMIOLOGICAL DATA; EVALUATION; EVIDENCE BASED MEDICINE; FLUORESCENCE; HUMAN; HYPERCOAGULABILITY; KIDNEY DISEASE; LEUKOCYTE; MEASUREMENT; METABOLISM; MOLECULAR DYNAMICS; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIALYLATION;

ACUTE-PHASE REACTION; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHEMISTRY, CLINICAL; DIABETES MELLITUS; HUMANS; KIDNEY DISEASES; LEUKOCYTES; METABOLIC SYNDROME X; N-ACETYLNEURAMINIC ACID; RISK FACTORS;

EID: 33745963749     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2006.02.010     Document Type: Review

References (159)

1. Viles-Gonzalez J.F., Anand S.X., Valdiviezo C., et al. Update in atherothrombotic disease. Mt. Sinai J. Med. 71 (2004) 97-208
2. WHO Chronic conditions: the global burden. World Health Organisation: http://www.who.int/chronic_conditions/burden/en/print.html. (2005) Accessed: [14.01.2005].
3. Pickup J.C., Chana T., Mattock M.B., Samuel A., and Mather H.M. Serum sialic acid concentrations in Asian diabetic patients in the UK. Diabet. Med. 13 (1996) 284-285
4. Crook M.A. Sialic acid and cardiovascular disease. Med. Biochem. 1 (1999) 123-130
5. Silllanaukee P., Ponnio M., and Jaakelainen I.P. Occurrence of sialic acids in healthy humans and different disorders. Eur. J. Clin. Invest. 29 (1999) 413-425
6. Schauer R. Sialic acids and their role as biological masks. TIBS 10 (1985) 357-360
7. Lindberg G., Eklund G.A., Gullberg B., and Rastam L. Serum sialic acid concentration and cardiovascular mortality. BMJ 302 (1991) 143-146
8. Lindberg G., Rastam L., Gullberg B., and Eklund G.A. Serum sialic acid concentration predicts both coronary heart disease and stroke mortality: multivariate analysis including 54 385 men and women during 20.5 year follow up. Int. J. Epidemiol. 21 (1992) 253-257
9. Tertov V.V., Orekhov A.N., Martsenyuk O.N., Perova N.V., and Smirnov V.N. Low-density lipoproteins isolated from the blood of patients with coronary heart disease induce the accumulation of lipids in human aortic cells. Exp. Mol. Pathol. 50 (1989) 337-347
10. Tertov V.V., Sobenin I.A., and Orekhov A.N. Characterisation of desialylated low-density lipoprotein which cause intracellular lipid accumulation. Int. J. Tissue Reac. 14 (1992) 155-162
11. Crook M.A., Tutt P., Simpson H., and Pickup J.C. Serum sialic acid and acute phase proteins in type 1 and type 2 diabetes mellitus. Clin. Chim. Acta 219 (1993) 131-138
12. Crook M.A., Tutt P., and Pickup J.C. Elevated serum sialic acid concentration in NIDDM and its relationship to blood pressure and retinopathy. Diabetes Care 16 (1993) 57-60
13. Pickup J.C., and Crook M.A. Is type II diabetes mellitus a disease of the innate immune system?. Diabetologia 41 (1998) 1241-1248
14. Crook M.A., Haq M., and Tutt P. Evaluation of three assays for the determination of serum total sialic acid. Clin. Biochem. 26 (1993) 449-454
15. Svennerholm L. Quantitative estimation of sialic acids. Biochim. Biophys. Acta 24 (1957) 604-611
16. Oegema T.R., and Cooper Jr. K.M. An improved automated periodate-resorcinol method for the determination of sialic acid. Anal. Biochem. 133 (1983) 233-238
17. Aminoff D. Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids. Biochem. J. 81 (1961) 384-392
18. Warren L. The thiobarbiturate assay for sialic acids. J. Biol. Chem. 234 (1959) 1971-1975
19. Gerbaut L., Rey E., and Lombart C. Improved automated determination of bound N-acetylneuramininc acid in serum. Clin. Chem. 19 (1973) 1285-1287
20. Delmotte P. The automated determination of blood serum sialic acid levels. Z. Klin. Chem. Klin. Biochem. 6 (1986) 46-48
21. Mattoo R.L., and Roseman S. Quantitative determination of sialic acid in the monosialoganglioside, GM1, by the thiobarbituric acid method. Anal. Biochem. 246 (1997) 30-33
22. Svennerholm L. Quantitative estimation of sialic acids. Acta Chem. Scand. 12 (1958) 547-554
23. Svennerholm L. Assay of sialic acids. Methods Enzymol. 6 (1963) 459-462
24. Crook M.A., Kargbo S., and Lumb P. Measurement of urine total sialic acid: comparison of an automated ultraviolet enzymatic method with a colorimetric assay. Br. J. Biomed. Sci. 59 (2002) 20-23
25. Roboz J., Suttajit M., and Bebeski J.G. Estimation of 2-deoxyribose interference in the thiobarbituric acid determination of N-acetylneuraminic acid in tumour cells by pH-dependent extraction with cyclohexanone. Ann. Biochem. 110 (1981) 380-388
26. Waters P.J., Lewry E., and Pennock C.A. Measurement of sialic acid in serum and urine: clinical applications and limitations. Ann. Clin. Biochem. 29 (1992) 625-637
27. Haverkamp J., Scauer R., Wember M., et al. Neuraminic acid derivatives newly discovered in humans. Hoppe-Seyler's Z. Physiol. Chem. 357 (1976) 1699-1705
28. Silver H.K.B., Karim K.A., Gray M.J., and Salinas F.P. A high performance liquid chromatography method for the determination of sialic acids. J. Chromatogr. 224 (1981) 381-388
29. Siskos P.A., and Spyridaki M.H. Determination of sialic acids in biological fluids using reversed-phase ion-pair high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 724 (1999) 205-212
30. Ishida J., Nakahara T., and Yamaguchi M. Measurement of N-acetylneuraminic acid in human serum and urine by high performance liquid chromatography with chemiluminescence detection. Biomed. Chromatogr. 6 (1992) 135-140
31. Lorentz K., Weiss T., and Kraas E. Sialic acid in human serum and cerebrospinal fluid. Comparison of methods and reference values. J. Clin. Chem. Clin. Biochem. 24 (1986) 189-198
32. Kim K.K., Escobedo J.O., St. Luce N.N., Rusin O., Wong D., and Strongin R.M. Postcolumn HPLC detection of mono- and oligosaccharides with a chemosensor. Org. Lett. 5 (2003) 5007-5010
33. Romero E.L., Pardo M.F., Porro S., and Alonso S. Sialic acid measurement by a modified Aminoff method: a time saving reduction in 2-thiobarbituric acid concentration. J. Biochem. Biophys. Methods 35 (1997) 129-134
34. Gressner A.M., and Henn K.H. Evaluation of a fully mechanised enzymatic kinetic determination of sialic acid. J. Clin. Chem. Clin. Biochem. 23 (1985) 781-785
35. Sughara K., Sugimoto K., Nomura O., and Usui T. Enzymatic assay of serum sialic acid. Clin. Chim. Acta (1980) 493-498
36. Simpson H., Chusney G.D., Crook M.A., and Pickup J.C. Serum sialic acid enzymatic assay based on microtitre plates: application for measuring capillary serum sialic acid concentrations. Br. J. Biomed. Sci 50 (1993) 164-167
37. Muniandy S., Qvist R., Zaini A., Chinna K., and Ismail I.S. A re-evaluation of plasma sialic acid determination using the periodate resorcinol method versus the enzymatic method. Southeast Asian J. Trop. Med. Public. Health 36 (2005) 1011-1013
38. Klenk E., and Langerbeins H. Orcinol method for measuring sialic acid. Hoppe-Seyler's Z. Physiol. Chem. 270 (1941) 185-193
39. Massamiri Y., Beljean M., Durand G., Feger J., Pays M., and Agneray J. Colorimetric assay of sialic acid by methyl-3-benzothiazolinone-2-hydrazone reactant. Anal. Biochem. 91 (1978) 618-625
40. Crook M.A. Determination of plasma or serum sialic acid. Clin. Biochem. 26 (1993) 31-38
41. Jourdian G.W., and Dean L. The sialic acids. IX. A periodate-resorcinol method for quantitative estimation of free sialic acids and their glycosides. J. Biol. Chem. 246 (1971) 430-435
42. Taniuchi K., Chifu K., Hayashi N., et al. A new enzymatic method for the determination of sialic acid in serum and its application for a marker of acute phase reactants. Kobe J. Med. Sci. 27 (1981) 91-102
43. Horiuchi T., and Kurokawa T. New enzymatic endpoint assay of serum sialic acid. Clin. Chim. Acta 182 (1989) 117-121
44. Teshima S., Tamai K., Hayashi Y., and Emi S. New enzymatic determination of sialic acid in serum. Clin. Chem. 34 (1988) 2291-2294
45. Sugiyama N., Saito K., Mizu H., Ito M., and Nagai Y. A high-precision selective determination method for free N-acetylneuraminic acid in human serum. Anal. Biochem. 170 (1988) 140-144
46. Hess H.H., and Rolde E. Fluorometric assay of sialic acids in brain gangliosides. J. Biol. Chem. 239 (1964) 3215-3220
47. Murayama J.I., Tomita M., Tsuji A., and Hamada A. Fluorometric assay of sialic acid. Anal. Biochem. 73 (1976) 535-538
48. Shukala A.K., and Schauer R. Fluorometric determination of unsubstituted and 9 (8)-0-acetylated sialic acid in the erythrocyte membrane. Hoppe-Seyler's Z. Physiol. Chem. 362 (1981) 236-237
49. Li K. Determination of sialic acids in human serum by reversed-phase liquid chromatography with fluorimetric detection. J. Chromatogr. 579 (1992) 209-213
50. Anumula K.R. Rapid quantitative determination of sialic acids in glycoproteins by high-performance liquid chromatography with a sensitive fluorescence detection. Anal. Biochem. 230 (1995) 24-30
51. Hammond K.S., and Papermaster D.S. Fluorometric assay of sialic acid in the picomole range. Anal. Biochem. 73 (1976) 535-538
52. Lindberg G., Iso H., Rastam L., Lundblad A., and Folsom A.R. Serum sialic acid and its correlates in community samples from Akita, Japan and Minneapolis, USA. Int. J. Epidemiol. 26 (1997) 58-63
53. Knuiman M.W., Watts G.F., and Divitini M.L. Is sialic acid an independent risk factor for cardiovascular disease? A 17 year follow-up study in Busselton, Western Australia. Ann. Epidemiol. 14 (2004) 627-632
54. Browning L.M., Jebb S.A., Mishra G.D., et al. Elevated sialic acid, but not CRP, predicts features of the metabolic syndrome independently of BMI in women. Int. J. Obes. Relat. Metab. Disord. 28 (2004) 1004-1010
55. Watts G.F., Crook M.A., Haq S., and Mandalia S. Serum sialic acid as an indicator of change in coronary artery disease. Metabolism 44 (1995) 147-148
56. Rastam L., Lindberg G., Folsom A.R., Burke G.L., Nilsson-Ehle P., and Lundblad A. Association between serum sialic acid concentration and carotid atherosclerosis measured by B-mode ultrasound. The ARIC Investigators. Atherosclerosis Risk in Communities Study. Int. J. Epidemiol. 25 (1996) 953-958
57. Gokmen S.S., Kilicli G., Ozcelik F., Ture M., and Gulen S. Association between serum total and lipid-bound sialic acid concentration and the severity of coronary atherosclerosis. J. Lab. Clin. Med. 140 (2002) 110-118
58. Wu E.B., Lumb P., Chambers J.B., and Crook M.A. Plasma sialic acid and coronary artery atheromatous load in patients with stable chest pain. Atherosclerosis 145 (1999) 261-266
59. Allain P., Olivier E., Le Brouil A., Benoit C., Geslin P., and Tadaie A. Increase of sialic acid concentration in the plasma of patients with coronary disease. Presse Med. 25 (1996) 96-98
60. Salomone O.A., Crook J.R., Hossein-Nia M., Holt D., and Kaski J.C. Serum sialic acid concentration is not associated with the extent or severity of coronary artery disease in patients with stable angina pectoris. Am. Heart J. 136 (1998) 620-623
61. Jenkins P.J., Harper R.W., and Nestel P.J. Severity of coronary atherosclerosis related to lipoprotein concentration. Br. Med. J. 2 (1978) 388-391
62. Mattila K.J., Valle M.S., Nieminen M.S., Valtonen W., and Hietaniemi K.L. Dental infections and coronary atherosclerosis. Atherosclerosis 103 (1993) 205-211
63. Lindberg G., Rastam L., Nilsson-Ehle P., et al. Serum sialic acid and sialoglycoproteins in asymptomatic carotid artery atherosclerosis. Atherosclerosis 146 (1999) 65-69
64. Haverkarte F., Thompson G., Pyke S.D.M., Gallimore J.R., and Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 349 (1997) 462-466
65. Mendall M.A., Patel P., Ballan L., Strachan D., and Northfield T.C. C-reactive protein and its relation to cardiovascular risk factors: a population-based cross sectional study. BMJ 312 (1996) 1061-1065
66. Crook M.A., Scott D.A., Stapleton J.A., Palmer R.M., Wilson R.F., and Sutherland G. Circulating concentrations of C-reactive protein and total sialic acid in tobacco smokers remain unchanged following one year of validated smoking cessation. Eur. J. Clin. Invest. 30 (2000) 861-865
67. Lindberg G., Rastam L., Gullberg B., Eklund G.A., and Tornberg S. Serum sialic acid concentration and smoking: a population based study. BMJ 303 (1991) 1306-1307
68. Crook M.A., Goldsmith L., Ameerally P., et al. Serum sialic acid, a possible cardiovascular risk factor is not increased in Fijian Melanesians with impaired glucose tolerance or impaired fasting glucose. Ann. Clin. Biochem. 39 (2002) 606-608
69. Wierzbicki A.S., Nishtar S., Lumb P.J., et al. Metabolic syndrome and risk of coronary heart disease in a Pakistani cohort. Heart 91 (2005) 1003-1007
70. Kario K., and Matsuo T. Relation between sialic acid concentrations and the haemostatic system in the elderly. BMJ 306 (1993) 1650-1651
71. Suzuki K., Ishida H., Taguchi Y., et al. The urinary concentration of sialic acid is increased in non-insulin dependent diabetic patients with microangiography: a possible useful marker for diabetic microangiopathy. Diabet. Med. 12 (1995) 1092-1096
72. Chen J.W., Gall M.A., Yokoyama H., Jensen J.S., Deckert M., and Parving H.H. Raised serum sialic acid concentration in NIDDM patients with and without diabetic nephropathy. Diabetes Care 19 (1996) 130-134
73. Crook M., Haq M., Haq S., and Tutt P. Plasma sialic acid and acute-phase proteins in patients with myocardial infarction. Angiology 45 (1994) 709-715
74. Crook M., and Tutt P. Serum sialic acid concentration in patients with hypertriglyceriaemia showing Frederickson's IIB phenotype. Clin. Sci. 83 (1992) 593-595
75. Crook M., Keria P., Lumb P., and Swaminathan R. Serum sialic acid, a reputed cardiovascular risk factor in south Asian men compared to European men. Ann. Clin. Biochem. 35 (1998) 242-244
76. Vijay V., Snehalatha C., Ramachandran A., and Jayaraman M. Serum sialic acid on south Indian type 2 diabetic patients with microvascular complications. Diabet. Med. 15 (1998) 176
77. Abdella N., Akanji A.O., Mojiminiyi O.A., Al Assoussi A., and Moussa M. Relation of serum total sialic acid concentrations with diabetic complications and cardiovascular risk factors in Kuwaiti Type 2 diabetic patients. Diabetes Res. Clin. Pract. 50 (2000) 65-72
78. Islam N., Kazmi F., Chusney G.D., Mattock M.B., Zaini A., and Pickup J.C. Ethnic differences in correlates of microalbuminuria in NIDDM. Diabetes Care 21 (1998) 385-388
79. Duncan B.B., Schmidt M.I., Pankow J.S., et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52 (2003) 1799-1805
80. Schmidt M.I., Duncan B.B., Sharrett A.R., et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353 (1999) 1649-1652
81. Islam N., Kazmi F., Chusney G.D., Mattock M.B., Zaini A., and Pickup J.C. Serum sialic acid and cardiovascular disease in Malay, Indian, Chinese subjects with NIDDM in Malaysia. Diabetes Res. 32 (1997) 77-85
82. Crook M.A., Pickup J.C., Lumb P.J., et al. Relationship between plasma sialic acid concentration and microvascular and macrovascular complications in type 1 diabetes: the EURODIAB Complications Study. Diabetes Care 24 (2001) 316-322
83. Pickup J.C., Roberts G.A., Kehely A.M., Pasapula C., Chusney G.D., and Mather H.M. Higher serum sialic acid in women than in men with NIDDM: possible relevance to increased cardiovascular risk in NIDDM women. Diabetes Care 20 (1997) 1496
84. Aflazi B., Bakri R.S., Bharma-Ariza P., et al. Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients. J. Nephrol. 16 (2003) 540-545
85. Bakri R.S., Afzali B., Covic A., et al. Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation. Clin. Transplant. 18 (2004) 201-204
86. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
87. Paoletti R., Gotto A.M., and Hajjar D.P. Inflammation in atherosclerosis and implications for therapy. Circulation 109 Suppl. III (2004) III20-III26
88. Pickup J.C., Mattock M.B., Chusney G.D., and Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40 (1997) 1286-1292
89. Stuart J., George A.J., Davies A.J., Aukland A., and Hurlow R.A. Haematological stress syndrome in atherosclerosis. J. Clin. Pathol. 34 (1981) 464-467
90. Funayama H., Ishikawa S.E., Kubo N., et al. Increases in interleukin-6 and matrix metalloproteinase-9 in the infarct-related coronary artery of acute myocardial infarction. Circ. J. 68 (2004) 451-454
91. Gokmen S.S., Kilicli G., Ozcelik F., and Gulen S. Serum total and lipid-bound SA levels following acute myocardial infarction. Clin. Chem. Lab. Med. 38 (2000) 1249-1255
92. Hanson V.A., Shettigar U.R., Loungani R.R., and Nadjicka M.D. Plasma sialidase activity in acute myocardial infarction. Am. Heart J. 1 (1987) 59-63
93. Sonmez H., Ozturk Z.G., Ulutin T., Domanic N., and Kokoglu E. Carbohydrate-deficient transferrin and sialidase levels in coronary heart disease. Thromb. Res. 99 (2000) 311-315
94. Butler J., Rocker G.M., and Westaby S. Inflammatory response to cardiopulmonary bypass. Ann. Thorac. Surg. 55 (1993) 552-559
95. Berkan O., Gol M.K., Gunay I., and Sagaban. Sialic acid is an indicator of inflammation due to cardiopulmonary bypass but not myocardial damage. J. Cardiovasc. Surg. 43 (2002) 489-493
96. Crook M.A., Earle K., Morocutti A., Yip J., Viberti G., and Pickup J.C. Serum sialic acid, a risk factor for cardiovascular disease, is increased in IDDM patients with microalbuminuria and clinical proteinuria. Diabetes Care 17 (1994) 305-310
97. Christ E.R., Cummings M.H., Lumb P.J., Crook M.A., Sonksen P.H., and Russell-Jones D.L. Growth hormone (GH) replacement therapy reduces serum sialic acid concentrations in adults with GH-deficiency: a double-blind placebo-controlled study. Clin. Endocrinol. 51 (1999) 173-179
98. Pfeifer M., Verhovec R., Zizek B., Prezelj J., Poredos P., and Clayton R.N. Growth hormone reverses early atherosclerotic changes in GH-deficient adults. J. Clin. Endocrinol. Metab. 84 (1999) 453-457
99. Millar J.S. The sialylation of plasma lipoproteins. Atherosclerosis 154 (2001) 1-13
100. Chappey B., Beyessen B., Foos E., et al. Sialic acid content of LDL in coronary artery disease: no evidence of desialylation in subjects with coronary artery disease and increased levels in subjects with extensive atherosclerosis and acute myocardial infarction. Arterio. Thromb. Vasc. Biol. 18 (1998) 876-883
101. Gracheva E.V., Samilova N.N., Golovanova N.K., et al. Sialytransferase activity of human plasma and aortic intima is enhanced in atherosclerosis. Biochim. Biophys. Acta 1586 (2002) 123-128
102. Bartlett A.L., and Stanley K.K. All low density lipoprotein particles are partially desialylated in plasma. Atherosclerosis 138 (1998) 237-245
103. Tertov V.V., Kaplun V.V., Sobenin I.A., and Orekhov A.N. Low density lipoprotein modification occurring in human plasma. Possible mechanism of in vivo lipoprotein desialylation as a primary step of atherogenic modification. Atherosclerosis 138 (1998) 183-195
104. Tanaka K., Tokumaru S., and Kojo S. Possible radical involvement of radical reactions in desialylation of LDL. FEBS Lett. 413 (1997) 202-204
105. Orekhov A.N., Tertov V.V., Sobenin I.A., et al. Sialic acid content of human low density lipoproteins affects their interaction with cell receptors and intracellular lipid accumulation. J. Lipid Res. 33 (1992) 805-817
106. Cerne D., Jurgens G., Ledinski G., Kager G., Greilberger J., and Lukac-Bajalo J. Relationship between the sialic acid content of low-density lipoprotein (LDL) and autoantibodies to oxidized LDL in the plasma of healthy subjects and patients with atherosclerosis. Clin. Chem. Lab. Med. 40 (2002) 2-15
107. Lindbohm N., Gylling H., Miettinen T.E., and Miettinen T.A. Statin increases the sialic acid content of LDL in hypercholesterolaemic patients. Atherosclerosis 151 (2000) 545-550
108. Orekhov A.N., Tertov V.V., Sobenin I.A., Akhmedzhanov N.M., and Pivovarova E.M. Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin. Int. J. Cardiol. 62 Suppl. 2 (1997) S67-S77
109. Chappey B., Myara I., Giral P., et al. Evaluation of the sialic acid content of LDL as a marker of coronary calcifcation and extra coronary atherosclerosis in asymptomatic hypercholesterolaemic subjects: PCV METRA Group. Arteriolscler. Thromb. Vasc. Biol. 15 (1995) 334-339
110. Lindbohm N., Gylling H., Rajaratnam R.A., and Miettinen T.A. Sialic acid content of low-density lipoprotein in women with coronary artery disease. J. Lab. Clin. Med. 136 (2000) 110-115
111. Lindbohm N., Gylling H., Miettinen T.E., and Miettinen T.A. Sialic acid content of LDL and lipoprotein metabolism in combined hyperlipidaemia and primary moderate hypercholesterolaemia. Clin. Chim. Acta 285 (1999) 69-84
112. Melajarvi N., Gylling H., and Miettinen T.A. Sialic acids and the metabolism of low density lipoprotein. J. Lipid Res. 37 (1996) 1625-1631
113. Tertov V.V., Kaplun V.V., Sobenin I.A., Boytsova E.Y., Bovin N.V., and Orekhov A.N. Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein. Atherosclerosis 159 (2001) 103-115
114. Tertov V.V., Sobenin I.A., Gabbasov Z.A., Popov E.G., and Orekhov A.N. Lipoprotein aggregation as an essential condition of intracellular lipid accumulation caused by modified low density lipoproteins. Biochem. Biophys. Res. Commun. 163 (1989) 489-494
115. Tertov V.V., and Orekhov A.N. Metabolism of native and naturally occurring multiple modified low density lipoprotein in smooth muscle cells of human aortic intima. Exp. Mol. Pathol. 64 (1997) 127-145
116. Fujikoka Y., Taniguchi T., Ishikawa Y., and Yokoyama M. Significance of acidic sugar chains of apolipoprotein B-100 in cellular metabolism of low density lipoproteins. J. Lab. Clin. Med. 136 (2000) 355-362
117. Orekhov A.N., Tertov V.V., Mukhin D.N., and Mikhailenko I.A. Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells: discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients. Biochem. Biophys. Res. Commun. 162 (1989) 206-211
118. Sobinen I.A., Orekhov A.N., Tertov V.V., and Smirnov V.N. Synergistic effect of desialylated and glycated low density lipoproteins on cholesterol accumulation in cultured smooth muscle aortic cells. Atherosclerosis 89 (1991) 151-154
119. Sobenin I.A., Tertov V.V., Koschinsky T., et al. Modified low density lipoprotein from diabetic patients causes cholesterol accumulation in human intimal aortic cells. Atherosclerosis 100 (1993) 41-54
120. Stratton P.D., Lumb P.J., Paganga G., Crook M.A., and Ferro A. Influence of sialic acid content of low-density lipoprotein particles on endothelium-dependent vasorelaxation in rabbit aorta. Atherosclerosis 154 (2001) 285-290
121. Reganon E., Martinez-Sales V., Vila V., et al. Relationship between fibrinogen protein and fibrinogen function in postmyocardial infarction patients. Thromb. Res. 104 (2001) 413-419
122. Libby P., and Simon D.L. Inflammation and thrombosis: the clot thickens. Circulation 103 (2001) 1718-1720
123. Reganon E., Vila V., Martinez-Sales V., et al. Association between inflammation and hemostatic markers in atherothrombotic stroke. Thromb. Res. 112 (2003) 217-221
124. Crook M.A., Couchman S., and Tutt P. Plasma fibrinogen and its relationship to plasma sialic acid in non-insulin-dependent diabetes mellitus. Blood Coagul. Fibrinolysis 7 (1996) 586-589
125. Wakabayashi I., and Masuda H. Relation of serum sialic acid to blood coagulation activity in type 2 diabetes. Blood Coagul. Fibrinolysis 13 (2002) 691-696
126. Reganon E., Vila V., Martinez-Sales V., Vaya A., and Aznar J. Inflammation, fibrinogen, thrombin generation in patients with previous myocardial infarction. Haematologica 87 (2002) 740-745
127. Hager K., Feigl S., and Platt D. Age dependency of the sialic acid content of fibrinogen. Consequences for erythrocyte aggregation. Arch. Gerontol. Geriatr. 12 (1991) 25-30
128. Yokoyama H., Jensen J.S., Myrup B., Mathiesen E.R., Ronn B., and Deckert T. Raised serum sialic acid concentration preceded onset of microalbuminuria in IDDM. Diabetes Care 19 (1996) 435-440
129. Gorog P., and Born G.V.R. Uneven distribution of sialic acids on the luminal surface of aortic endothelium. Br. J. Exp. Pathol. 64 (1983) 418-424
130. Cross A.S., Sakarya S., Rifat S., et al. Recruitment of murine neutrophils in vivo through endogenous sialidase activity. J. Biol. Chem. 78 (2003) 4112-4120
131. Sakarya S., Rifat S., Zhou J., et al. Mobilization of neutrophil sialidase activity desialylates the pulmonary vascular endothelial surface and increase resting neutrophil adhesion to and migration across the endothelium. Glycobiology 14 (2004) 481-494
132. Theilmer G., Lenaerts T., Remacie C., Collen D., Vermylen J., and Hoylaerts M.F. Circulating activated platelets assist THP-1 monocytoid/endothelial cell interaction under shear stress. Blood 94 (1999) 2725-2734
133. Rabini R.A., Vignini A., Martarelli D., et al. Evidence for reduction of pro-atherosclerotic properties in platelets from healthy centenarians. Exp. Gerontol. 38 (2003) 367-371
134. Hadengue A.L., Del-Pino M., Simon A., and Levenson J. Erythrocyte disaggregation shear stress, sialic acid and cell aging in humans. Hypertension 32 (1998) 324-330
135. Temelkova-Kurktschiev T., Koehler C., Henkel E., and Hanefeld M. Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes. Cardiovasc. Res. 56 (2002) 277-283
136. Temelkova-Kurktschiev T., Siegert G., Bergmann E., et al. Subclinical inflammation is strongly related to insulin resistance but not in impaired insulin secretion in a high risk population for diabetes. Metabolism 51 (2002) 743-749
137. Leinonen E.S., Hiukka A., Hurt-Camejo E., et al. Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes. J. Int. Med. 256 (2004) 119-127
138. Fruhbeck G., Gomez-Ambrosi J., Muruzabal F.J., and Burrell M.A. The adipocyte: a model for integration of endocrine and metabolic signalling in energy metabolism regulation. Am. J. Physiol. Endocrinol. Metab. 280 (2001) E827-E847
139. Crook M.A., Miell J., Ameerally P., Lumb P., Singh N., Russell-Jones D., et al. Serum sialic acid, a reputed cardiovascular risk factor, is related to serum leptin concentrations in Fijians. Clin. Chim. Acta 331 (2003) 1-5
140. Morrish N.J., Wang S.L., Stevens L.K., et al. Mortality and causes of death in the WHO multinational study of vascular diseases in diabetes. Diabetologia 44 Suppl. 2 (2001) S14-S21
141. Pickup J.C., Mattock M.B., Crook M.A., Chusney G.D., Burt D., and Fitzgerald A.P. Serum sialic acid concentration and coronary heart disease in NIDDM. Diabetes Care 18 (1995) 1100-1103
142. Yavuz D.G., Ersoz O., Kucukkaya B., et al. The effect of losartan and captopril on glomerular basement membrane anionic charge in a diabetic rat model. J. Hypertens. 17 (1999) 1217-1223
143. Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabetic Med. 21 (2003) 203-207
144. Joushulathi P., Salomaa V., Rasi V., Vahtera E., and Palosuo T. The association of C-reactive protein, serum amyloid A and fibrinogen with prevalent coronary heart disease-baseline findings of the PAIS project. Atherosclerosis 156 (2001) 451
145. Patel V.B., Robbins M.A., and Topoi E.J. C-reactive protein: a 'golden marker' for inflammation and coronary artery disease. Cleve Clin. J. Med. 68 (2001) 521
146. Ridker P.M., Stampfer M.J., and Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein a, and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285 (2001) 2481
147. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R., and Haffner S. Chronic subclinical inflammation as part of the insulin resistance syndrome. Circulation 102 (2000) 42-47
148. Festa A., D'Agostino R., Tracy R., and Haffner S. Elevated levels of acute-phase proteins and plasminogen activator inhibitor (PAI-1) in the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes 51 (2002) 1131-1137
149. Rajpura K.B., Patel P.S., Chawda J.G., and Shah R.M. Clinical significance of total and lipid bound sialic acid levels in oral pre-cancerous conditions and oral cancer. J. Oral. Pathol. Med. 34 (2005) 263-267
150. Matysik A., Toczolowski J., Starzycka M., Jakubowska-Solarska B., Solski J., Romanowska-Dixon B., et al. The level of total sialic acid, alfa-antitrypsin, ceruloplasmin in the serum of patients with choroidal melanoma. Ann. Univ. Mariae Curie Sklodowska 57 (2002) 238-244
151. Akcay F., Taysi S., Uslu C., Dogru Y., and Gumustekin K. Levels of soluble intercellular adhesion molecule-1 and total sialic acid in serum of patients with laryngeal cancer. Jpn. J. Clin. Oncol. 31 (2001) 584-588
152. Wongkham S., Boonla C., Kongkham S., Wongkham C., Bhudhisawasdi V., and Sripa B. Serum total sialic acid in cholangiocarcinoma patients: an ROC curve analysis. Clin. Biochem. 34 (2001) 537-541
153. Feijoo-Carnero C., Rodriguez-Berrocal F.J., Paez de la Cadena M., Ayude D., de Carlos A., and Martinez-Zorzano V.S. Clinical significance of preoperative serum sialic acid levels in colorectal cancer: utility in the detection of patients at high risk of tumor recurrence. Int. J. Biol. Markers 19 (2004) 38-45
154. Ponnio M., Sillanaukee P., and Franck J. Serum sialic acid levels are increased during relapse to alcohol drinking: a pilot study. Alcohol Clin. Exp. Res. 26 (2002) 1365-1367
155. Romppanen J., Punnonen K., Anttila P., Jakobsson T., Blake J., and Niemela O. Serum sialic acid as a marker of alcohol consumption: effect of liver disease and heavy drinking. Alcohol Clin. Exp. Res. 26 (2002) 1234-1238
156. Arif S., Najeeb-ul-Haq, Hanif R., Khan A.S., Jamil-ur-Rehman, and Mufti T.A. Variations of serum sialic acid level in liver cirrhosis. J. Ayub. Med. Coll. Abbottabad. 17 (2005) 54-57
157. Dogan H., Pasaoglu H., Ekinciler O.F., and Tatlisen N. A comparative study of total protein, total and lipid associated serum sialic acid levels in patients with Behcet's disease and control groups. Acta Ophthalmol. (Copenh) 70 (1992) 790-794
158. Crook M.A., Khandhadia S., Lumb P., Ridha A., and Hussain A. No difference in serum sialic acid in type 2 diabetic patients from the United Arab Emirates with and without diabetic retinopathy. Diabetes Res. Clin. Pract. 47 (2000) 147-150
159. Deepa R., Rema M., and Mohan V. Lack of association between serum sialic acid levels and retinopathy in type 2 diabetic patients. Diabetes Res. Clin. Pract. 41 (1998) 165-169